| Identification | Back Directory | [Name]
Dehydrocorydaline chloride | [CAS]
10605-03-5 | [Synonyms]
Dehydrocorydaline chloride
13-Methylpalmatine chloride
Dehydrocorydaline chloride, 99.95% | [Molecular Formula]
C22H24ClNO4 | [MDL Number]
MFCD01937870 | [MOL File]
10605-03-5.mol | [Molecular Weight]
401.883 |
| Chemical Properties | Back Directory | [Melting point ]
191-193 °C (decomp) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 20 mg/ml | [form ]
A solid | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
Dehydrocorydaline chloride (13-Methylpalmatine chloride) is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates PARP[1]. Dehydrocorydaline chloride elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities[2]. Dehydrocorydaline chloride shows strong anti-malarial effects (IC50?=38 nM), and low cytotoxicity (cell viability?>?90%) using P. falciparum 3D7 strain[3]. | [Biological Activity]
Dehydrocorydaline chloride (13-Methylpalmatine chloride) is an alkaloid isolated from the traditional Chinese medicine Corydalis yanhusuo. It regulates Bax, Bcl-2 protein expression; activates caspase-7, caspase-8, and inactivates PARP. Also Dehydrocorydaline chloride can enhance the activation of p38 MAPK and has anti-inflammatory and anti-cancer effects. . | [in vitro]
Dehydrocorydaline significantly inhibits MCF-7 cell proliferation in a dose-dependent manner, which can be reversed by a caspase-8 inhibitor, Z-IETD-FMK. Dehydrocorydaline increases DNA fragments without affecting ΔΨm. Western blotting assay shows that dehydrocorydaline dose-dependently increases Bax protein expression and decreases Bcl-2 protein expression. | [in vivo]
Dehydrocorydaline (3.6, 6 or 10 mg/kg, ip) shows a dose-dependent anticiceptive effect in the acetic acid-induced writhing test and significantly attenuates the formalin-induced pain responses in mice. In the formalin test , dehydrocorydaline decreases the expression of caspase 6 (CASP6), TNF-α, IL-1β and IL-6 proteins in the spinal cord. These findings confirm that Dehydrocorydaline has antinociceptive effects in mice. | [target]
| [IC 50]
Plasmodium | [References]
[1] Xu Z, et al. Dehydrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells. Am J Chin Med. 2012;40(1):177-85. DOI:10.1142/S0192415X12500140
[2] Yoo M, et al. Dehydrocorydaline promotes myogenic differentiation via p38 MAPK activation. Mol Med Rep. 2016 Oct;14(4):3029-36. DOI:10.3892/mmr.2016.5653
[3] Nonaka M, et al. Screening of a library of traditional Chinese medicines to identify anti-malarial compounds and extracts. Malar J. 2018 Jun 25;17(1):244. DOI:10.1186/s12936-018-2392-4
[4] Yin ZY, et al. Antinociceptive effects of dehydrocorydaline in mouse models of inflammatory pain involve the opioid receptor and inflammatory cytokines. Sci Rep. 2016 Jun 7;6:27129 DOI:10.1038/srep27129 |
|
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|